Concepedia

Author

R-H. Xu

Sun Yat-sen University Cancer Center

Also Known As

R H Xu, R-H. Xu, Rongqin Xu

56

Publications

163

Citations

7

H-Index

17

Concepts

All Affiliations

Sun Yat-sen University Cancer CenterSun Yat-sen UniversitySir Run Run Shaw HospitalThird Affiliated Hospital of Harbin Medical UniversityNational Cancer Center Hospital East
RX

About

R-H. Xu is an author at Sun Yat-sen University Cancer Center specializing in pathology, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

62

2

Pathology

4

4

62

3

Gastroenterology

2

2

27

4

Immunology

1

1

12

5

Pharmacology

1

1

11

R-H. Xu

×

5

Publications

72

Citations

5

H-Index

YearCitations

1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)

R-H. Xu, F. Wang, Chengxu Cui,

Annals of Oncology

2021

23

LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

R-H. Xu, D-Y. Oh, Ken Kato,

Annals of Oncology

2023

16

550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study

R-H. Xu, Ye Xu, Dongyao Yan,

Annals of Oncology

2023

12

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Kohei Shitara, S-E. Al-Batran, Y-J. Bang,

Annals of Oncology

2020

11

860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma

Fei Han, Fei Wang, Y-R. Shi,

Annals of Oncology

2023

10

Page 1